Serum levels of soluble Fas/APO‐1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases

There are two major forms of the Fas molecule, membranous Fas and soluble Fas (sFas). To clarify the clinical significance of sFas in autoimmune diseases, we designed a sandwich ELISA to determine serum concentrations of sFas and its molecular structure, and we then analysed the correlation between levels of sFas and laboratory findings in patients with SLE and other autoimmune diseases. The levels of serum sFas were significantly higher in SLE patients than in subjects with other autoimmune diseases and in healthy donors, and the frequency of a positive serum sFas was much greater in SLE patients with high SLE disease activity index scores than in those with low scores. In addition, sFas‐positive SLE patients showed a significant difference in various laboratory parameters from sFas‐negative SLE patients. Serial measurements of serum sFas levels in SLE patients with active disease revealed that the elevated level of sFas dramatically decreased with improvement in clinical and laboratory findings, following corticosteroid therapy. We propose that the serum level of sFas can serve as an appropriate marker for evaluating SLE disease activity. Serum sFas is heterogeneous with respect to molecular structure, thus several mechanisms are involved in the generation of sFas.

[1]  N. Goel,et al.  Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. , 1995, Arthritis and rheumatism.

[2]  A. Kawasaki,et al.  Metalloproteinase-mediated release of human Fas ligand , 1995, The Journal of experimental medicine.

[3]  P. Krammer,et al.  Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[4]  Warren Strober,et al.  Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome , 1995, Cell.

[5]  F. Rieux-Laucat,et al.  Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. , 1995, Science.

[6]  T. Yokota,et al.  Expression of the Fas ligand in cells of T cell lineage. , 1995, Journal of immunology.

[7]  G. Fiucci,et al.  Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. , 1995, Journal of immunology.

[8]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[9]  P. Krammer,et al.  Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) , 1995, Nature.

[10]  S. Ju,et al.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation , 1995, Nature.

[11]  Seamus J. Martin,et al.  Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas , 1995, Nature.

[12]  A. Tsutsumi,et al.  Up‐regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia , 1995, Clinical and Experimental Immunology.

[13]  S. Yonehara,et al.  Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes. , 1994, International Immunology.

[14]  C. Bombardier,et al.  Kidney biopsy in systemic lupus erythematosus , 1994 .

[15]  M. Harigai,et al.  Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. , 1994, Clinical immunology and immunopathology.

[16]  J. Mountz,et al.  Autoimmune disease. A problem of defective apoptosis. , 1994, Arthritis and rheumatism.

[17]  R. Testi,et al.  Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase , 1994, The Journal of experimental medicine.

[18]  S. Yonehara,et al.  Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  N. Jenkins,et al.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand , 1994, Cell.

[20]  Matthew J. Brauer,et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.

[21]  P. Krammer,et al.  The apoptosis-1/Fas protein in human systemic lupus erythematosus. , 1994, The Journal of clinical investigation.

[22]  P. Krammer,et al.  Differential expression of APO‐1 on human thymocytes: Implications for negative selection? , 1994, European journal of immunology.

[23]  J. Russell,et al.  Autoimmune gld mutation uncouples suicide and cytokine/proliferation pathways in activated, mature T cells , 1993, European journal of immunology.

[24]  J. Mountz,et al.  Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene , 1993, The Journal of experimental medicine.

[25]  K. Elkon,et al.  The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn , 1993, The Journal of experimental medicine.

[26]  C. Weaver,et al.  Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  T. Uede,et al.  Transcriptional repression and differential splicing of Fas mRNA by early transposon (ETn) insertion in autoimmune lpr mice. , 1993, Biochemical and biophysical research communications.

[28]  S. Nagata,et al.  Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Golstein,et al.  Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity , 1993, The Journal of experimental medicine.

[30]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[31]  M. Pawlita,et al.  Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. , 1992, The Journal of biological chemistry.

[32]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.

[33]  N. Copeland,et al.  The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. , 1992, Journal of immunology.

[34]  Atsushi Hase,et al.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.

[35]  H. Holtmann,et al.  Soluble forms of tumor necrosis factor receptors (TNF‐Rs). The cDNA for the type I TNF‐R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. , 1990, The EMBO journal.

[36]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[37]  P. Möller,et al.  Monoclonal antibody-mediated tumor regression by induction of apoptosis. , 1989, Science.

[38]  S. Yonehara,et al.  A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor , 1989, The Journal of experimental medicine.

[39]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[40]  D. Nelson,et al.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. , 1985, Journal of immunology.

[41]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[42]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[43]  C. Pearson,et al.  A COMPUTER‐ASSISTED ANALYSIS OF 153 PATIENTS WITH POLYMYOSITIS AND DERMATOMYOSITIS , 1977, Medicine.

[44]  C. Bombardier,et al.  Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. , 1994, Arthritis and rheumatism.

[45]  S. Nagata,et al.  Fas and Fas ligand: a death factor and its receptor. , 1994, Advances in immunology.

[46]  M. Akizuki,et al.  Criteria for Sjögren's syndrome in Japan. , 1986, Scandinavian journal of rheumatology. Supplement.